Drug Trial Radar · NCT06907043
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Last checked: Nov 20, 2026Latest source record: Aug 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
130
Planned (sponsor's estimate)
Start
Apr 30, 2025
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Eikon TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Impact Therapeutics, Inc.
- First posted
- Apr 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 89 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pancreatic cancer with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) genes. Condition or disease Intervention/treatment Phase Advanced Solid Tumors Drug: EIK1004 (IMP1707) Phase 1/Phase 2
Conditions
- Advanced Solid Tumors
Interventions
EIK1004-001 (IMP1707-001)Drug
PARP1 selective inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants who experience a Dose-Limiting Toxicity (DLT)Time frame: (Timeframe: up to 28 days)
- Number of participants with adverse events, treatment emergent adverse events or serious adverse eventsTime frame: (Time Frame: 1 month post last dose of EIK1004 (IMP1707)
Locations
10 sites in 3 countries. Site status is shown where the registry gives one.
Sarah Cannon Research Institute at HealthOne
Denver, Colorado · Recruiting
Florida Cancer Center
Lake Mary, Florida · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
MD Anderson
Houston, Texas · Recruiting
NEXT Oncology
San Antonio, Texas · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
PASO Medical
Frankston, Victoria, Australia · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, China · Recruiting
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China · Recruiting
Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)
Jinan, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.